Membrane disrupting drugs such as antimicrobial peptides are being considered as a solution to counter the problem of antibiotic resistance. Although it can be intuitively imagined that bacteria will eventually develop resistance to this class of drugs as well, the concern has largely been ignored. Drawing upon the experimental data from the resistance of Staphylococcus aureus to antimicrobial peptides, we theoretically model the membrane adaptation under drug pressure. Using our model, we simulate the serial passage experiments with and without the drug pressure, and use the comparisons with experiments to estimate the unknown kinetic parameters. While the development of resistance to enzyme or membrane targeting drugs are both driven by spontaneous mutations, an additional lysylation step required in the latter slows the development of resistance. By quantifying the tradeoff between the gain in fitness under drug pressure and a loss in growth due to membrane modification, our model shows a fast reversal of membrane composition in drug free conditions, re-sensitizing the bacterium to the drugs.
Introduction
The discovery of penicillin dramatically increased survival rate by lowering mortality. Almost hundred years after this discovery, the world health organization (WHO) claims that antibiotic resistance is one of the major health threats of the 21st century. A rapid increase of bacterial resistance against almost all clinically used antibiotics is creating a real threat towards human health.
1 For example, the treatment of Staphylococcus aureus (S. aureus) infections has become problematic due to the evolution of multi drug resistant strains.
Daptomycin, a cyclic lipopeptide, which interacts with the membrane in a Ca 2+ dependent mechanism was considered to be effective against S. aureus, 2 but recent reports suggest the rise of daptomycin resistant strains. Similarly A. baumanii has also evolved into a multidrug resistant (MDR) [3] [4] [5] bacteria which has already developed resistance against carbapenem, 6 one of the last line drugs. Bacterial adaptation, primarily driven by mutations in the enzymes that are targeted by drugs, is the principal reason for this resistance. This crisis suggests a need to search for new antimicrobial agents, with non-conventional mechanism of action.
Antimicrobial peptides (AMPs) are found in almost all organisms 7 and their widespread role in innate defence has been recognized. 8, 9 Antibiotics such as AMPs and their mimics which target bacterial membranes instead of their enzymes are being considered as effective alternatives to combat antibiotic resistance and many of them are already in clinical trials.
10
Some AMPs target bacterial macromolecules 11 like DNA, 12 RNA 13 or proteins. 14 However, it is now accepted that membrane disruption such as by barrel stave 15 and carpet 16 mechanisms, is a key factor for AMP activity. 14, 17, 18 Cationic AMPs are believed to be drawn to the membrane, mostly consisting of negatively charged phosphatidylglycerol (PG) and cardiolipin (CL), by electrostatic interactions, whereupon, hydrophobic forces play a key role in pore formation and membrane disruption. 19, 20 Since mammalian cells mostly consist of zwitterionic phospholipids, it is believed that AMPs do not act on them.
19,20
Clinical introduction of membrane active drugs, including AMPs, is new. While it is commonly cited that bacteria do not develop resistance against AMPs, [21] [22] [23] it is not technically true. Serial passage studies in which bacterial colonies are subjected to systematically increasing drug challenge, show a development of resistance, although it is slower than the conventional drugs. Several studies have shown that the bacterial membranes adapt, mainly by surface charge modification in the presence of AMPs. For example, Staphylococcus aureus,
24
Listeria monocytogenes, 25 Mycobacterium tuberculosis, 26 Bacillus anthracis 27 and Rhizobium tropici 28 have enzymatic mechanisms to add positively charged lysines to the phospholipids.
Specifically in Staphylococcus aureus (S. aureus), the antimicrobial peptide-sensing (aps) system in the membrane senses the presence of AMP, which activates the Multiple peptide resistance factor (MprF). MprF catalytically mediates the reaction of converting a fraction of PG to lysyl-PG (LPG), and thus increases the positive charge of the membrane and repels AMPs, as shown, for example, in the development of resistance to daptomycin.
29,30
Mutant S. aureus with out the capability of LPG production shows reduced virulence in in vivo studies. 31 The development especially of MRSA in S. aureus has been noted with 
Effect of drug on bacterial death and growth
Increase in LPG production: In the presence of AMPs, in addition to the biosynthesis of PG, CL, LPG, an additional enzymatic conversion of PG to LPG is activated. We assume that an SNP in MprF that is required to drive this conversion happens in 1 out of 10 7 cell divisions and continues to be present under drug pressure. The rate of PG conversion gets upregulated with the increasing MprF levels. We assume an upregulation factor of f M prF after each cell division since the mutation, increasing by a factor
The only k P G→LP G that was measured 42 was for E. coli (0.055min −1 ) rather than S. aureus and after the bacteria adapted to a high concentration of the drug. We optimize the k basal P G→LP G to be used in our model, as well as the multiplicative factor f M prF , a posteriori by comparing the results from our model with the experimental data (Results Section).
Fitness cost: Gaining antibiotic resistance by gene mutation is associated with a fitness cost, i.e., the resistant bacteria has lower growth rate than the susceptible strain. [43] [44] [45] [46] [47] Susceptible strains maintain homeostasis in the cell, aided by the membrane phospholipids.
Under drug pressure, when the membrane composition changes, it affects the growth rates.
When bacterial enzymes are targeted, the fitness may be regained over the generations, with compensatory mutations. However, the same is not true when the membrane undergoes a surface charge modification. We assume a linear drop in fitness, Figure 2) , where f max is the maximum drop in fitness when the lysylation is at the maximum level (24% LPG in the membrane) as observed in the S. aureus data and the value of f max that was determined by comparing the results from model with the experimental data (Results Section). This correction factor was applied to the growth rate at different membrane compositions. However, we found with our calculations that the general conclusions were not sensitive to small changes in the estimates of the two factors, f max and f M prF .
Death rate: Unlike enzyme active drugs which are inactive in the stationary phase, AMPs continue to act depending only on the membrane composition rather than the growth phase.
Motivated by the data from the CB118 strain of S. aureus, we assume the death rate is highest at 12% LPG and drops to zero beyond 24% LPG. In our model, we use a sigmoidal dependence of death factor on the %LPG, Figure 3) to model this gradual loss of sensitivity to drug as the membrane composition changes.
Results

Simulating serial passage
Each passage in our simulation begins with a colony of 10 9 bacterial cells and grows over a period of 24 hours, during which the colony grows to a size of 10 13 (approximately).
A schematic of how the bacterial resistance develops or is lost in our model is shown in 
Upregulation of MprF and evolution of resistance
Reversal of resistance upon AMP withdrawal
In order to understand how the bacteria behave when AMP is withdrawn from the medium, a colony starting with all mutant cells was studied for its evolution during the successive passages. Similar to the study under drug pressure, we simulated passages of 24 hours, with the last 5.5 hours being considered as a stationary phase. The two competing effects are the reversal of the mutations that were beneficial under AMP with a rate 10 −7 and a reduced growth rate with the now higher LPG at no additional selective advantage for these species as the drugs are absent. After each cell division of the mutant cell, it produces a heterogenous distribution of the revertant mutant strains, which were binned in increments of 2% LPG as R1, R2,..., R7 for further analysis.
The revertant cells will have the higher fitness over the mutant cell. So, the revertant cells will divide faster than the mutant cells and eventually dominate the population. The number of days that the revertant cell will take to dominate over the mutant cell is depends on the fitness factor f max . We simulated 20 days of serial passage under the no-drug condition, and parametrically scan through different values of f max (Supplementary Figure 6) . The results obtained as the change in the numbers of sensitive cells, and the overall %LPG in the medium are shown in Figure 4 . This comparison was used to obtain f max = 0.3, which is used in the rest of our calculations.
Resistance to enzyme versus membrane targeting drugs
When a traditional drug hinders the activity of a bacterial enzyme, bacteria with mutations in the targeted enzyme get preferentially selected. Due to the mutations, a susceptible strain directly converts to the resistant strain and the fitness of the bacteria decreases rapidly.
We simulated the difference in the patterns of resistance between enzyme and membrane targeted cases over time and the results are shown in Figure 5 . A conclusion that emerges from this comparison is that the resistance to AMPs which is a two step process -an SNP is required to initiate the development of resistance, followed by an increase in LPG over time. The resistance to AMPs is thus not instantaneous even after the beneficial mutation in the bacteria. For an easy comparison, the gain of fitness in the resistant strain whether the enzyme or the membrane was targeted, was considered to be the same, i.e., the f f itness with 24% LPG under AMP drug pressure was used as the fitness of the resistant strain with mutant bacterial enzyme under the pressure of traditional drug.
Bacterial response to sudden removal and reintroduction of AMPs
Some studies previously reported that the antibiotic resistance remains persistent due to the compensatory mutation. 43, 45, 48 But this is not the case for all antibiotics, as other studies established the reversion of resistance. Methicillin resistant strain of S. aureus (MRSA) has lower fitness than the methicillin susceptible strains, and a rapid decrease in MRSA when the use of methicillin is reduced has been noticed. 49 Because, this resistance carries a fitness cost, a successive switch on and switch off of the antibiotic treatment can be a proper way to treat bacterial infection without causing resistance. 47, [50] [51] [52] [53] It is hard to establish a correlation between the serial passage tests which are conducted on the scale of days with To simulate the time evolution of bacteria in presence of AMP, we considered f max =0.3 and f M prF =1.009 and to simulate the time evolution of bacteria in presence of traditional drug, we consider the fitness drop same as in case of AMP, i.e., 0.3. extremely high drug doses and the development of clinical resistance which happens over years, which is usually attributed to poor adherence. While a population based model for resistance may be explored as a separate work, we use our model, to study the consequences of a cyclic dosage, where the antibiotic treatment is repeatedly switched on and off. Starting with the 10 9 bacteria, we studied the fate of the bacteria in a successive switch on and switch off dosage with the antibiotics. The results from an overall 60 day serial passage test with alternating periods with and without antibiotics for 10 days each are shown in Figure 6 . AMPs on the contrary happens in two stages. In the first stage, a mutation similar to the one in the enzymes targeted by the conventional drugs occurs. This mutation by itself does not provide drug resistance, but rather prepares it for resistance by charge modification.
4.Discussion
Resistance is not instantaneous
The next step is the upregulation of MprF which will increase the LPG levels, and thus over time resistance is achieved. This fundamental difference is responsible for the slower development of resistance in serial passage tests when using AMPs, typically requiring twice as many passages to reach the same level of resistance ( Figure 5 ).
Another interesting aspect this two step process of drug resistance offers is that it raises the possibility of using a secondary drug target against MprF. For the next generation drugs, one can consider the MprF as a secondary drug target. MprF has two pockets binding PG and tRN A lys molecules respectively; and these could be targeted to inhibit lysylation. 
Resistant strain is not unique
Fitness can not be regained without loss of resistance
When under the pressure of a conventional drug, an enzyme mutates, the fitness can be regained by a compensatory mutation while still maintaining the drug resistance. 54 But in case of AMPs, the factor that determines the resistance or the fitness is the membrane phospholipid composition. In the presence of AMPs, SNP in MprF results in an increase in %LPG, inadvertently compromising the fitness. To maintain homeostasis, the bacterium has to reverse the charge modifications which will also reverse the resistance, resulting in a higher death rate. When using AMPs, the fitness is intricately and inversely coupled to the drug resistance. A second mutation in MprF is more likely to cause a loss of lysylation that helps regain fitness. From our model, it does not seem easy to compensate for the loss of fitness and to recover the viability.
Reversal differentiates qualitatively
While resistance is not instantaneous, the loss of MprF factor upon drug withdrawal is almost instantaneous, 55 getting affected within a few cell divisions. This ad hoc nature of the drug resistance, where the resistance appears under AMP drug pressure and relaxes when the drug pressure is relaxed is qualitatively different from the drug resistant that can remain persistent due to compensatory mutations. The intricate competition between fitness which can not be regained by compensatory mutations forces the bacterium to revert to a drug-sensitive stage.
Other models of drug resistance such as by the release of peptidases have not been considered in this work, as they are considered secondary to the surface modifications. Other secondary resistance mechanisms and the chance that the resistance to membrane active drugs remains persistent because of other mechanisms need to be studied as a followup.
Conclusions
In this work, we studied in detail the mechanism of development of resistance to AMPs with The increase in the number of bacterial cells over time, and the gaussian factor which is supposed to capture the phase dependent variation in growth rate are both shown over one single passage lasting a day. The choice of the gaussian is motivated by the fact that the growth rate is a derivative of the population (sigmoidal) over time. 
